BioNano Genomics Completes $9 Million Public Offering

BioNano Genomics ( (BNGO) ) has shared an update.

On September 16, 2025, Bionano Genomics, Inc. announced a public offering of 5,000,000 shares of common stock and warrants, raising approximately $9 million in net proceeds, which will be used for working capital and general corporate purposes. The offering closed on September 17, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent, and the company agreed to certain restrictions on issuing additional shares for a specified period, impacting its financial strategy and market operations.

The most recent analyst rating on (BNGO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioNano Genomics stock, see the BNGO Stock Forecast page.

Spark’s Take on BNGO Stock

According to Spark, TipRanks’ AI Analyst, BNGO is a Neutral.

BioNano Genomics’ overall stock score is primarily impacted by its weak financial performance and valuation, which reflect ongoing challenges in profitability and cash flow. While the earnings call provided some positive insights, such as improved margins and cost reductions, these are overshadowed by the broader financial difficulties and bearish technical indicators.

To see Spark’s full report on BNGO stock, click here.

More about BioNano Genomics

Bionano Genomics, Inc. is a company that provides genome analysis solutions aimed at transforming the understanding of genomes through optical genome mapping (OGM) solutions, diagnostic services, and software. They offer OGM solutions for basic, translational, and clinical research applications, as well as genome analysis software and nucleic acid extraction and purification solutions using proprietary isotachophoresis technology.

Average Trading Volume: 435,861

Technical Sentiment Signal: Sell

Current Market Cap: $8.42M

See more insights into BNGO stock on TipRanks’ Stock Analysis page.